Investigational drug · Phase 2
TL118
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Solid Tumor.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "TL118"
First trial start
2023
Mar 16, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TL118", any sponsor or status.
Conditions studied
As listed on its trial records.
- Solid Tumor
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "TL118" as an intervention, largest first.
- Phase IIB Clinical Trial of Hamsa-1™ in Metastatic Castration Resistant Prostate Cancer (CRPC)Status unknown
Tiltan Pharma Ltd.Industry
NCT00684970 · 100 participants (planned) · Start Mar 2009 · Primary completion Feb 2014
Drug: Hamsa-1™ TL-118 · For: Metastatic Castration Resistant Prostate Cancer (CRPC)
Sites: Haifa, Israel; Tel Aviv, Israel; Tel HaShomer, Israel · 5 sites in all
Tiltan Pharma Ltd.Industry
NCT01509911 · 99 participants · Start Jan 2012 · Primary completion Oct 2016
Drug: TL-118; Gemcitabine · For: Metastatic Pancreatic Cancer
Sites: Atlanta, Georgia; White Plains, New York; Tsrifin, Israel · 10 sites in all
Teligene USIndustry
NCT06010342 · 60 participants (planned) · Start Mar 16, 2023 · Primary completion Dec 2027
Drug: TL118 Capsule · For: Solid Tumor
Sites: Glendale, California; Dallas, Texas; Houston, Texas · 20 sites in all
Tiltan Pharma Ltd.Industry
NCT01659502 · 10 participants (planned) · Start Dec 2013 · Primary completion Oct 2014
Drug: TL-118 · For: Pancreatic Cancer
Sites: Jerusalem, Israel
Newest research
PubMed records naming it or its code names, newest first.
- TL-118 and gemcitabine drug combination display therapeutic efficacy in a MYCN amplified orthotopic neuroblastoma murine model--evaluation by MRI.
Komar-Stossel C, Gross E, Dery E, et al. · PLoS One 2014
- TL-118-anti-angiogenic treatment in pancreatic cancer: a case report.
Breuer S, Maimon O, Appelbaum L, et al. · Med Oncol 2013
- Improved efficacy of a novel anti-angiogenic drug combination (TL-118) against colorectal-cancer liver metastases; MRI monitoring in mice.
Edrei Y, Gross E, Corchia N, et al. · Br J Cancer 2012
Also in development for Solid Tumor
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- JAB-21822Glecirasib Citrate, KRAS G12C inhibitorPhase 310 trials
Allist Pharmaceuticals, Inc. · Non-small Cell Lung Cancer, KRAS P.G12C, Solid Tumor
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- PD-1 monoclonal antibodyPhase 39 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Nasopharyngeal Carcinoma (NPC), Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
- PD-1 inhibitorPhase 38 trials
BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
- RC148Phase 38 trials
RemeGen Co., Ltd. · Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations, Solid Tumor, Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.